A5083355007- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Inhalation and Respiratory Drug Delivery
- RNA Interference and Gene Delivery
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Respiratory viral infections research
- Advanced Drug Delivery Systems
- Vaccine Coverage and Hesitancy
- Multiple Sclerosis Research Studies
- Immune Cell Function and Interaction
- Mast cells and histamine
- Viral Infections and Immunology Research
- Viral gastroenteritis research and epidemiology
- Mass Spectrometry Techniques and Applications
- interferon and immune responses
- Bacterial Infections and Vaccines
- Biochemical effects in animals
- Endoplasmic Reticulum Stress and Disease
- Bacteriophages and microbial interactions
- Long-Term Effects of COVID-19
- Protein purification and stability
- Biosensors and Analytical Detection
University of North Carolina at Chapel Hill
2023-2025
University of North Carolina Health Care
2024
Mexican Social Security Institute
2020-2023
Hospital de Especialidades
2020-2021
Centro Medico Nacional Siglo XXI
2020-2021
Universidad Nacional Autónoma de México
2021
Multiple sclerosis (MS) is a severe autoimmune disorder that wreaks havoc on the central nervous system, leading to spectrum of motor and cognitive impairments. There no cure, current treatment strategies rely broad immunosuppression, leaving patients vulnerable infections. To address this problem, our approach aims induce antigen-specific tolerance, much-needed shift in MS therapy. We have engineered tolerogenic therapy consisting spray-dried particles made degradable biopolymer, acetalated...
Abstract Current FDA‐approved influenza vaccines are limited by variable year to efficacy, low immunogenicity, and poor stability outside of cold‐chain storage. Polymeric microparticles can overcome many these issues provide an improved vaccine platform. Here, acetalated dextran microparticle platform is used encapsulate a broadly active COBRA immunogen the adjuvant cGAMP. Microparticles fabricated via highly scalable electrospray method. Mice vaccinated with loaded cGAMP produced antibodies...
Currently licensed vaccine adjuvants offer limited mucosal immunity, which is needed to better combat respiratory infections such as influenza. Mast cells (MCs) are emerging a target for new class of adjuvants. Here, we developed and characterized nanoparticulate adjuvant composed an MC activator [mastoparan-7 (M7)] TLR ligand (CpG). This novel nanoparticle (NP) was co-formulated with computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA), against influenza strains. M7...
Abstract Influenza virus outbreaks are a major burden worldwide each year. Current vaccination strategies inadequate due to antigenic drift/shift of the and elicitation low immune responses. The use computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) immunogens subvert constantly mutating viruses; however, they poorly immunogenic on their own. To increase immunogenicity subunit vaccines such as this, adjuvants can be delivered with vaccine. For example, agonists...
Introduction Several effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, current production capacity falls short of meeting global demand. Therefore, it is crucial to further develop novel vaccine platforms that can bridge distribution gap. AVX/COVID-12 a vector-based utilizes Newcastle Disease virus (NDV) present SARS-CoV-2 spike protein immune system. Methods This study aims analyze antigenicity...
Salmonella enterica serovar Typhi (S. Typhi) porins, OmpC and OmpF, are potent inducers of the immune response against S. in mice humans. Vaccination with porins induces protection 500 LD50 Typhi, life-lasting bactericidal antibodies effector T cell responses mice; however, nature memory compartment its contribution to remains unknown. In this work, we firstly observed that vaccination situ (skin) CD4+ CD8+ responses. Analysis porin-specific functional skin cells showed IFN-gamma-...
Abstract Several effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, current production capacity falls short of meeting global demand. Therefore, it is crucial to further develop novel vaccine platforms that can bridge distribution gap. AVX/COVID-12 a vector-based utilizes Newcastle Disease virus (NDV) present SARS-CoV-2 spike protein immune system. This study analyses antigenicity candidate by...
In the face of urgent need for a COVID-19 vaccine, currently more than 90 vaccine candidates are being developed using different strategies, such as inactivated or attenuated SARS-CoV-2 virus, viral vectors expressing antigens this nucleic acids purified proteins. These vaccines in preclinical development and at least six them have already been injected into volunteers safety clinical trials. However, characteristics protective immune responses still unknown; therefore, there is not evidence...
T lymphocytes (or cells) are characterized by having an essential role in the control of acute viral infections. SARS-CoV-2 infection is that mainly affects respiratory tract causing COVID-19 disease, which presents with mild, moderate and critical symptoms can lead to death patient. The induction populations CD4+ CD8+ cell a functional memory phenotype could be decisive replication therefore determinants course disease. In this opinion article, we will review reported evidence regarding...